Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...
| Main Authors: | , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Korean Association for the Study of Intestinal Diseases
2022-01-01
|
| 叢編: | Intestinal Research |
| 主題: | |
| 在線閱讀: | http://irjournal.org/upload/pdf/ir-2020-00117.pdf |